ACAD R&D to Revenue
Acadia Pharmaceuticals Inc · R&D to Revenue
ACAD R&D to Revenue
Latest reported26.48%period ending
ACAD Quarterly R&D/Revenue (223.33% → 26.48%)
Latest values, visible window
High-resolution chart · PNG
ACAD r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 26.4824% | |
| 28.6755% | |
| 29.8452% | |
| 31.5214% | |
| 29.4637% | |
| 32.0342% | |
| 38.8021% | |
| 26.5997% | |
| 31.5061% | |
| 28.9942% | |
| 28.8871% | |
| 74.1444% | |
| 35.5681% | |
| 58.3681% | |
| 55.4898% | |
| 62.2244% | |
| 56.216% | |
| 111.5937% | |
| 51.1953% | |
| 44.4982% | |
| 49.4137% | |
| 53.4687% | |
| 51.3326% | |
| 99.5903% | |
| 58.3953% | |
| 80.6457% | |
| 58.4993% | |
| 66.2064% | |
| 80.9086% | |
| 84.0595% | |
| 80.8833% | |
| 91.0934% | |
| 81.6501% | |
| 80.3716% | |
| 99.1208% | |
| 102.3694% | |
| 112.1575% | |
| 231.6433% | |
| 252.6166% | |
| 489.9962% | |
| 21,111.3402% | |
| 569,375% | |
| 120,388.2353% | |
| 48,023.0769% | |
| 1,837,900% | |
| 407,375% | |
| 38,685.1064% | |
| 113,013.3333% | |
| 49,282.1429% | |
| 38,893.3333% | |
| 21,418.9189% | |
| 3,022.5% | |
| 1,576.9401% | |
| 1,062.3501% | |
| 1,289.7368% | |
| 126.5095% | |
| 746.5776% | |
| 1,115.7778% | |
| 752.381% | |
| 711.9863% | |
| 938.0435% | |
| 1,014.2529% | |
| 13.4363% | |
| 215.7757% | |
| 219.4602% | |
| 272.6207% | |
| 442.9621% | |
| 378.4394% | |
| 658.1868% | |
| 3,356.6845% | |
| 3,737.2308% | |
| 4,750.7092% | |
| 9,059.887% | |
| 1,882.2581% | |
| 1,091.4719% | |
| 864.0266% | |
| 559.3674% | |
| 625.5612% | |
| 615.8488% | |
| 828.5641% | |
| 651.5152% | |
| 399.1328% | |
| 413.6021% | |
| 219.5427% | |
| 260.9998% | |
| 263.0139% | |
| 588.4161% | |
| 374.5779% | |
| 532.3028% | |
| 622.286% | |
| 0% | |
| 0% | |
| 189.5235% | |
| 223.3294% |